소마젠

950200KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

45.9 / 100

Reference Date: 2026-06-10

Financial Score12.5 / 40

News Sentiment20.4 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 21.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SomaGen provides diverse genomic analysis services, including NGS, CES, single-cell analysis, and proteomics, collaborating with institutions like the US NIH and global pharmaceutical companies through a B2B model, establishing a strong presence in the North American market. It also expands into the B2C sector with DTC genetic testing and microbiome analysis services, leveraging partnerships with companies such as 10x Genomics and Olink Proteomics to enhance its technological capabilities.

Number of Employees

88people

Average Salary

78.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 48.804.0Point

PBR

—Industry Average 1.433.5Point

ROE

-15.09Industry Average 0.940.0Point

Well below industry avg

Debt Ratio

33.35Industry Average 12.510.0Point

2.7x industry avg (risky)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲29.7% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.9% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 81.7

Positive
[바이오사 리포트] 소마젠, 본업 BEP 접근…변수는 일본 DTC 손실
소마젠은 올해 1분기 외형성장과 손실 축소로 본업 BEP 접근에 성공했으나, 연결기준 손실은 여전히 지속되고 있다.
Positive
소마젠, 1Q 매출액 876만달러…"수익성 개선+실적 성장 가속"
소마젠의 1분기 매출액이 전년 동기 대비 증가하며 수익성 개선과 성장 가속을 보여주었다.
Positive
“적자 97% 줄였다”…소마젠, 1분기 ‘사상 최대 매출’에 흑자전환...
소마젠이 1분기 사상 최대 매출 달성과 흑자 전환으로 긍정적인 턴어라운드를 이루었다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,710Won52-week high 4,12552-week low 2,710

1-month return0.0Point

1m -21.79% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15